Toxicities Associated with CAR T-Cell Therapy — An Interview with Dr Matthew Lunning
Hematologic Oncology Update
00:00
Comparing commercial CAR T products
Dr Lunning compares axicabtagene, lisocabtagene and brexucabtagene on manufacturing time, toxicity profile, and institutional preferences.
Play episode from 16:10
Transcript
